ArticleJournal of endocrinological investigation2026
Effect of breastfeeding on cardiometabolic risk in patients with polycystic ovary syndrome.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study investigated whether breastfeeding (BF) is associated with a reduction in persistent hypertension (PH) and glucose metabolism impairment in patients with polycystic ovary syndrome (PCOS) who experienced pregnancy-induced hypertension (PIH) and/or gestational diabetes mellitus (GDM).
methodsThis secondary observational analysis utilized data from two prospective cohort studies involving 241 participants (101 PCOS patients; 140 controls) with a history of GDM and/or PIH. At 18 months post-delivery, patients underwent physical examinations, blood pressure monitoring, and biochemical assays, including oral glucose tolerance tests. Feeding practices were categorized as exclusive BF, partial BF, or formula feeding (FF).
resultsPatients with PCOS demonstrated significantly shorter BF durations (9.6 ± 7.0 vs. 12.6 ± 5.9 months; P < 0.001) and lower exclusive BF rates (39.6% vs. 62.9%; P < 0.001) compared to controls. At 18 months, the composite cardiometabolic outcome prevalence was 55.4% in the PCOS group versus 11.4% in controls (P < 0.001). Multivariate analysis identified exclusive BF as a potent independent factor associated with a significantly lower risk (adjusted OR 0.14, 95% CI 0.05-0.38; P < 0.001) of cardiometabolic impairment.
conclusionBreastfeeding is associated with a significant reduction in long-term cardiometabolic risks in women with PCOS following complicated pregnancies. Supporting and optimizing lactation may represent a valuable non-pharmacological strategy to consider for this high-risk population.
Indexed as
Identifiers
42329360What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.